Mucosal healing and deep remission: what does it mean?
Mucosal healing and deep remission: what does it mean?
复制标题
粘膜愈合和深度缓解：这意味着什么？
DOI：
10.3748/wjg.v19.i43.7552
复制
发表时间：
2013
影响因子：
4.3
通讯作者：
P. Lakatos
中科院分区：
文献类型：
--
作者：
G. Rogler;S. Vavricka;A. Schoepfer;P. Lakatos
在不同的含义和不同的定义下使用特定术语一直是科学混乱的根源。当我们致力于炎症性肠病（IBD）的循证医学时，情况也是如此：如果含义随着时间的推移或定义发生变化，“粘膜愈合”或“深度缓解”等术语作为临床试验的终点或日常患者护理的治疗目标可能会导致误解。首先看看术语及其定义的发展，评估其内在和上下文无关的问题，然后分析当今临床研究和试验中的不同相关性，似乎是有用的。这样做的目的是为了更清楚地了解这些术语背后的临床发现的真正影响。它也可能导致在未来的研究中更好地定义这些术语的使用。近年来，“粘膜愈合”和“深度缓解”作为治疗IBD患者的新靶点被引入。一些临床试验、队列研究或初始队列提供的数据表明，当粘膜愈合时，长期病程更好。然而，目前尚不清楚持续或增加的治疗措施是否有助于或改善临床缓解患者的粘膜愈合。为了回答这个问题，临床试验正在进行中。应注意清楚地说明IBD活动的水平。在这篇综述文章中，作者旨在总结目前关于粘膜愈合和深度缓解的证据，并试图强调它们在胃肠病学家日常决策中的价值和地位。
The use of specific terms under different meanings and varying definitions has always been a source of confusion in science. When we point our efforts towards an evidence based medicine for inflammatory bowel diseases (IBD) the same is true: Terms such as "mucosal healing" or "deep remission" as endpoints in clinical trials or treatment goals in daily patient care may contribute to misconceptions if meanings change over time or definitions are altered. It appears to be useful to first have a look at the development of terms and their definitions, to assess their intrinsic and context-independent problems and then to analyze the different relevance in present-day clinical studies and trials. The purpose of such an attempt would be to gain clearer insights into the true impact of the clinical findings behind the terms. It may also lead to a better defined use of those terms for future studies. The terms "mucosal healing" and "deep remission" have been introduced in recent years as new therapeutic targets in the treatment of IBD patients. Several clinical trials, cohort studies or inception cohorts provided data that the long term disease course is better, when mucosal healing is achieved. However, it is still unclear whether continued or increased therapeutic measures will aid or improve mucosal healing for patients in clinical remission. Clinical trials are under way to answer this question. Attention should be paid to clearly address what levels of IBD activity are looked at. In the present review article authors aim to summarize the current evidence available on mucosal healing and deep remission and try to highlight their value and position in the everyday decision making for gastroenterologists.
登录
查看更多内容
影响因子：
2.5
作者：
Stylianou E
通讯作者：
Stylianou E
DOI：
--
发表时间：
2012
期刊：
--
影响因子：
--
作者：
通讯作者：
--
影响因子：
7
作者：
Häsler R;Feng Z;Bäckdahl L;Spehlmann ME;Franke A;Teschendorff A;Rakyan VK;Down TA;Wilson GA;Feber A;Beck S;Schreiber S;Rosenstiel P
通讯作者：
Rosenstiel P
回肠克罗恩病中潘氏细胞防御素表达的降低与炎症无关，但与 NOD2 1007fs 基因型有关。
影响因子：
24.5
作者：
Bevins,CL;Stange,EF;Wehkamp,J
通讯作者：
Wehkamp,J
影响因子：
12.6
作者：
Rosenberg, Laura;Nanda, Kavinderjit S.;Zenlea, Talia;Gifford, Anne;Lawlor, Garrett O.;Falchuk, Kenneth R.;Wolf, Jacqueline L.;Cheifetz, Adam S.;Goldsmith, Jeffrey D.;Moss, Alan C.
通讯作者：
Moss, Alan C.